Gastrointestinal Diseases Therapeutics Market Size to grow by USD 18526.1 million between 2024-2028
According to a research report “ Gastrointestinal Diseases Therapeutics Market” by Drug Class (Anti-inflammatory and immunosuppressors, Acid neutralizers, Others) Type (Branded, Generics) Geography (North America, Asia, Europe, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 18526.1 million, at a CAGR of 6.81% during the forecast period. The global gastrointestinal diseases therapeutics market is experiencing significant growth due to the increasing prevalence of conditions such as gallstones, ulcerative colitis, fissures, hemorrhoids, irritable bowel disease (IBD), and gastroesophageal reflux disease (GERD). Factors including improper diet, sedentary lifestyles, stress, food sensitivities, and bacterial or viral infections contribute to the rising incidence of both chronic and acute gastrointestinal diseases. Chronic gastrointestinal diseases, such as IBD, can lead to serious medical complications and disabilities if left untreated. IBD, a prevalent gastrointestinal disease, causes inflammation of the gastrointestinal tract, with Crohn's disease and ulcerative colitis being its most common forms. Effective treatment and diagnosis of these conditions are crucial for mitigating their impact on patients' quality of life and overall health..
Browse market data tables, figures, and in-depth TOC on “Gastrointestinal Diseases Therapeutics Market” by Drug Class (Anti-inflammatory and immunosuppressors, Acid neutralizers, Others) Type (Branded, Generics) Geography (North America, Asia, Europe, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Drug Class, the Anti-inflammatory and immunosuppressors segment is projected to dominate the market size in 2024
In the realm of gastrointestinal diseases therapeutics, the segment for anti-inflammatory and immunosuppressors holds significant potential for growth. This segment caters to the treatment of inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, through the use of anti-inflammatory drugs. These medications are essential in mitigating the pain and inflammation associated with these conditions. Both steroidal and nonsteroidal anti-inflammatory drugs (NSAIDs) serve this purpose, with the former exhibiting potent anti-inflammatory effects, while the latter primarily targeting pain relief. The increasing prevalence of IBDs, the burgeoning focus of pharmaceutical vendors on developing biologics, and the positive treatment outcomes among patients with IBDs are key factors fueling the expansion of this market segment.
By Type, Branded segment is expected to hold the largest market size for the year 2024
Branded gastrointestinal disease therapeutics represent proprietary medications and treatment solutions, developed, manufactured, and commercialized by pharmaceutical companies under their distinctive brand names. These offerings are safeguarded by patents, providing the exclusive right to market and sell the branded drugs for a defined period. The patent protection enables pharmaceutical firms to recover their substantial research and development investments and generate profits. Extensive clinical trials and research are conducted to ensure the safety and efficacy of these branded therapeutics prior to regulatory approval for treating various gastrointestinal diseases.
North America is forecasted to hold the largest market size by region in 2024
The gastrointestinal diseases therapeutics market represents a significant business opportunity due to the rising prevalence of gastrointestinal disorders worldwide. Key players in this market focus on developing innovative therapies to address unmet medical needs, leveraging advanced technologies and research. Market growth is driven by factors such as an aging population, increasing awareness, and improving healthcare infrastructure. Strategic collaborations and partnerships are crucial for companies to expand their product portfolios and gain a competitive edge.
The Gastrointestinal Diseases Therapeutics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
The gastrointestinal (GI) diseases therapeutics market is witnessing significant growth due to the increasing prevalence of chronic digestive diseases, such as Crohn's disease, ulcerative colitis, and irritable bowel syndrome (IBS). Novel therapies, including targeted drugs, are being developed to address the unmet needs of patients with these conditions. For instance, biologics and small molecule drugs are being used to treat autoimmune diseases like Crohn's disease, ulcerative colitis, Scleroderma, psoriasis, Lupus, Rheumatoid arthritis, and Multiple sclerosis. Furthermore, the market is witnessing a surge in the development of drugs for gastrointestinal cancers and type 1 diabetes. The use of advanced technologies like gene therapy and stem cell therapy is also gaining momentum in the treatment of GI disorders. The market is expected to grow at a robust pace in the coming years due to the increasing demand for effective treatments for these debilitating conditions. GI disorders, including gastroesophageal reflux disease (GERD), also contribute significantly to the market growth. Overall, the GI diseases therapeutics market offers substantial opportunities for growth, driven by the increasing burden of chronic GI diseases and the development of novel therapies.
Market Research Overview
The Gastrointestinal (GI) Diseases Therapeutics Market encompasses a wide range of products including Online pharmacies, OTC drugs such as Laxative preparations and Anti-emetics, and prescription medications like injectable segment. Key brands include Natalizumab, Infliximab, Certolizumab, Adalimumab, Humira, Linzess, and Biosimilars of TNF blockers like Renflexis, Remicada, Inflectra, and Tysabri. Patent expirations have led to the entry of generic versions and new players in the market. Targeted drugs and novel therapies are gaining popularity for chronic digestive diseases like Crohn's disease, IBS, Ulcerative proctitis, and others including Scleroderma, Psoriasis, Lupus, Rheumatoid arthritis, Multiple sclerosis, Type 1 diabetes, and Gastrointestinal cancers. H2 antagonists, Aminosalicylates, Proton pump inhibitors, and Biologics continue to dominate the market. Telemedicine and Clinical trials are transforming the delivery and development of GI drugs respectively. Other GI conditions like Duodenal ulcer, Gastric ulcer, and Peptic ulcer disease are also addressed with various treatments. Online providers, Retail pharmacies, and Drug stores, as well as Hospital pharmacies, offer these medications to patients.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
